A library of 1,2,3-triazole-incorporated thymol-1,3,4-oxadiazole derivatives (6–18) hasbeen synthesized and tested for anticancer and antimicrobial activities. Compounds 7, 8, 9, 10, and 11 exhibited significant antiproliferative activity. Among these active derivatives, compound 2-(4-((5-((2-isopropyl-5-methylphenoxy)methyl)-1,3,4-oxadiazol-2-ylthio)methyl)-1H-1,2,3-triazol-1-yl)phenol (9) was the best compound against all three tested cell lines, MCF-7 (IC50 1.1 μM), HCT-116 (IC50 2.6 μM), and HepG2 (IC50 1.4 μM). Compound 9 was found to be better than the standard drugs, doxorubicin and 5-fluorouracil. These compounds showed anticancer activity through thymidylate synthase inhibition as they displayed significant TS inhibitory activity with IC50 in the range 1.95–4.24 μM, whereas the standard drug, Pemetrexed, showed IC50 7.26 μM. The antimicrobial results showed that some of the compounds (6, 7, 9, 16, and 17) exhibited good inhibition on Escherichia coli (E. coli) and Staphylococcus aureus (S. aureus). The molecular docking and simulation studies supported the anticancer and antimicrobial data. It can be concluded that the synthesized 1,2,3-triazole tethered thymol-1,3,4-oxadiazole conjugates have both antiproliferative and antimicrobial potential.
我们合成了一个 1,2,3-三唑并入胸腺酚-1,3,4-恶二唑衍生物库(6-18),并对其进行了抗癌和抗菌活性测试。化合物 7、8、9、10 和 11 具有显著的抗增殖活性。在这些活性衍生物中,化合物 2-(4-((5-(((2-异丙基-5-甲基苯氧基)甲基)-1,3,4-恶二唑-2-基硫基)甲基)-1H-1,2,3-三唑-1-基)苯酚(9)是对所有三种测试细胞株 MCF-7(IC50 1.1 μM)、HCT-116(IC50 2.6 μM)和 HepG2(IC50 1.4 μM)效果最好的化合物。化合物 9 的抗癌效果优于标准药物多柔比星和 5-氟尿嘧啶。这些化合物通过抑制胸腺嘧啶合成酶而显示出抗癌活性,因为它们显示出显著的 TS 抑制活性,IC50 在 1.95-4.24 μM 之间,而标准药物培美曲塞的 IC50 为 7.26 μM。抗菌结果表明,一些化合物(6、7、9、16 和 17)对大肠杆菌和金黄色葡萄球菌具有良好的抑制作用。分子对接和模拟研究支持了这些抗癌和抗菌数据。由此可以得出结论,合成的 1,2,3-三唑系百里酚-1,3,4-恶二唑共轭物具有抗增殖和抗菌潜力。